small molecule

VORANIGO

VORASIDENIB

Loss of exclusivityJanuary 2039latest FDA-listed patent expiry

CompanySERVIER PHARMACEUTICALS LLC

Drug detail

Brand name	VORANIGO
Active ingredient	VORASIDENIB
Strength	10MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	August 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
11345677	January 2039	substance, product
11844758	December 2035	use U-3977
12433895	July 2034	use U-4286
10172864	July 2034	substance, product
9579324	July 2034	substance

Regulatory exclusivity

Code	Expires
ODE-491	August 2031
NCE	August 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from SERVIER PHARMACEUTICALS LLC